TG Therapeutics (TGTX) Receives Daily News Sentiment Rating of 0.16
News headlines about TG Therapeutics (NASDAQ:TGTX) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TG Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.4505552217163 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s analysis:
- Seesawing Stocks: Limelight Networks, Inc., (NASDAQ: LLNW), TG Therapeutics, Inc., (NASDAQ: TGTX), The Mosaic … – Stocks In The News (press release) (tradingnewsnow.com)
- TG Therapeutics (TGTX) Receives New Coverage from Analysts at B. Riley (americanbankingnews.com)
- ETFs with exposure to TG Therapeutics, Inc. : November 30, 2017 (finance.yahoo.com)
- TG Therapeutics, Inc. (NASDAQ:TGTX) – Is the Stock Overvalued? – Nasdaq Journal (press release) (nasdaqjournal.com)
- TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 (finance.yahoo.com)
TG Therapeutics (TGTX) traded down $0.28 during mid-day trading on Friday, reaching $8.33. 1,253,424 shares of the company’s stock were exchanged, compared to its average volume of 1,202,484. TG Therapeutics has a 1 year low of $4.10 and a 1 year high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. equities analysts predict that TG Therapeutics will post -1.86 EPS for the current year.
TGTX has been the subject of several analyst reports. B. Riley initiated coverage on shares of TG Therapeutics in a research note on Friday. They issued a “buy” rating and a $21.50 target price for the company. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. SunTrust Banks reissued a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a research note on Tuesday, October 3rd. HC Wainwright reissued a “buy” rating and issued a $33.00 target price (up from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. Finally, ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $26.25.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.